I have established a Chlamydia trachomatis research program independently funded by federal and non-federal sources that has studied the epidemiology, clinical manifestations, diagnosis, treatment, natural history, immunology, and genetic determinants of genital C. trachomatis infection and its outcomes. I have evaluated C. trachomatis-specific humoral immune responses using a novel C. trachomatis EB ELISA and C. trachomatis-specific cellular immune responses using tools such as intracellular cytokine staining, ELISPOT, and multiplex. I have evaluated host genetic determinants through HLA typing and DNA sequencing methods. I have conducted chlamydia treatment trials, including both recommended treatments and investigational drugs, and have explored the relationship of C. trachomatis characteristics, such as the OmpA genotype and chlamydia load, in relation to chlamydia outcomes. The ultimate goal of my research is to contribute to development of a chlamydia vaccine. Until a chlamydia vaccine is available, I will continue to study chlamydia treatments and other aspects of chlamydia prevention and control. In the course of my research, I have mentored trainees at different levels, and I am able to contribute to mentoring future physician scientists in my position as Clinical Associate Director of the University of Alabama at Birmingham (UAB) Medical Scientist Training Program. I have over 15 years of clinical experience in the evaluation and management of sexually transmitted infections, which has been critical to designing and implementing translational research.
William Michael Geisler, MD, MPH